Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

326
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
326
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

425
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
425
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

554
β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in...
554
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

406
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
406
Antihypertensive Drugs: Types of β-Blockers01:28

Antihypertensive Drugs: Types of β-Blockers

618
β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and...
618
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

720
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
720

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Targeting Inflammation in Obesity and the Cardiovascular-Kidney-Metabolic (CKM) Syndrome Spectrum: A Narrative Review.

Obesity facts·2026
Same author

Erythrocyte and Platelet Indices at Admission and Discharge Stratify Long-Term Cardiovascular Risk After Invasive Treatment of Myocardial Infarction.

Journal of clinical medicine·2026
Same author

Inflammatory Biomarkers and Their Associations with Arrhythmic Burden Following SGLT2-I Treatment in Chronic Heart Failure-A Subanalysis of the ERASe Trial.

Journal of clinical medicine·2026
Same author

Hostile Aortic Neck Anatomy Increases Risk of Intraoperative Type I Endoleak After Endovascular Aneurysm Repair: Analysis of the Vascular Quality Initiative.

The Journal of surgical research·2026
Same author

A Systematic Review of Literature to Assess the Role and Utilization of Palliative Care in Vascular Surgery Patients.

Annals of vascular surgery·2026
Same author

Editorial: Next-generation technologies and multidisciplinary integration for oral cancer diagnosis and treatment.

Frontiers in oral health·2026

Related Experiment Video

Updated: Jun 17, 2025

Complete and Partial Resuscitative Endovascular Balloon Occlusion of the Aorta for Hemorrhagic Shock
06:30

Complete and Partial Resuscitative Endovascular Balloon Occlusion of the Aorta for Hemorrhagic Shock

Published on: May 19, 2022

5.9K

Beta Blockers are Associated with Increased Mortality Without a Decrease in Reinterventions After Endovascular

Raquel Vicario-Feliciano1, Ahsan Zil-E-Ali1, Faisal Aziz1

  • 1Division of Vascular Surgery, Heart and Vascular Institute, Pennsylvania State Milton S. Hershey Medical Center, Hershey, PA.

Annals of Vascular Surgery
|August 5, 2024
PubMed
Summary
This summary is machine-generated.

Beta blockers (BBs) do not reduce reinterventions after endovascular aortic aneurysm repair (EVAR). Patients on BBs had a higher risk of mortality and graft occlusion reintervention at one year.

More Related Videos

A New Murine Model of Endovascular Aortic Aneurysm Repair
08:51

A New Murine Model of Endovascular Aortic Aneurysm Repair

Published on: July 7, 2013

14.4K
The Intra-Aortic Balloon Pump
06:13

The Intra-Aortic Balloon Pump

Published on: February 5, 2021

21.2K

Related Experiment Videos

Last Updated: Jun 17, 2025

Complete and Partial Resuscitative Endovascular Balloon Occlusion of the Aorta for Hemorrhagic Shock
06:30

Complete and Partial Resuscitative Endovascular Balloon Occlusion of the Aorta for Hemorrhagic Shock

Published on: May 19, 2022

5.9K
A New Murine Model of Endovascular Aortic Aneurysm Repair
08:51

A New Murine Model of Endovascular Aortic Aneurysm Repair

Published on: July 7, 2013

14.4K
The Intra-Aortic Balloon Pump
06:13

The Intra-Aortic Balloon Pump

Published on: February 5, 2021

21.2K

Area of Science:

  • Vascular Surgery
  • Cardiovascular Research
  • Medical Interventions

Background:

  • Sac behavior post-endovascular aortic aneurysm repair (EVAR) and its effect on long-term survival remain unclear.
  • Limited multicenter trials investigate beta blockers (BBs) impact on EVAR sac behavior.
  • Previous studies show BBs do not benefit abdominal aortic aneurysm sac regression in general or specific populations.

Purpose of the Study:

  • To assess the association between beta blockers (BBs) and sac behavior after EVAR.
  • To evaluate the impact of BBs on reintervention rates and mortality following EVAR.

Main Methods:

  • Analysis of patients undergoing EVAR from the Vascular Quality Initiative (2003-2021).
  • Stratification of patients based on BB use at discharge.
  • Primary outcomes included mortality and reintervention at 30 days and 1 year, with analysis of reintervention causes.

Main Results:

  • A total of 50,411 patients were studied; 57.3% were on BBs.
  • No significant difference in overall reinterventions between BB and no-BB groups (P=0.061).
  • Patients on BBs showed lower reintervention for graft occlusion (11.77% vs 18.70%, P=0.002) but higher 30-day and 1-year mortality (P<0.001).
  • A 26% higher risk of 1-year mortality was observed in patients on BBs (HR: 1.26 [1.10-1.41], P<0.001).

Conclusions:

  • Beta blockers (BBs) do not decrease endovascular reinterventions after EVAR.
  • Patients on BBs exhibit a higher mortality rate post-EVAR.
  • The theoretical benefits of BBs on aneurysm behavior are not supported by this large-scale analysis.